Cantor Fitzgerald Weighs in on Metsera FY2025 Earnings

Metsera, Inc. (NASDAQ:MTSR - Free Report) - Research analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for Metsera in a report released on Tuesday, February 25th. Cantor Fitzgerald analyst P. Agrawal forecasts that the company will earn ($3.38) per share for the year. Cantor Fitzgerald has a "Overweight" rating on the stock.

Several other brokerages have also weighed in on MTSR. Guggenheim assumed coverage on Metsera in a research note on Tuesday, February 25th. They issued a "buy" rating and a $56.00 price target for the company. Evercore ISI started coverage on Metsera in a research report on Tuesday, February 25th. They issued an "outperform" rating for the company. Finally, Bank of America started coverage on Metsera in a research report on Tuesday, February 25th. They set a "buy" rating and a $38.00 target price on the stock.

Metsera Trading Up 15.0 %

Shares of Metsera stock traded up $3.72 during trading hours on Thursday, reaching $28.50. The stock had a trading volume of 719,169 shares, compared to its average volume of 620,578. Metsera has a twelve month low of $24.19 and a twelve month high of $32.81.

Metsera Company Profile

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.